Skip to content
lifestyle.marketresearchjournals.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Quince Therapeutics, Inc.
Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease
October 9, 2026
Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026
September 17, 2026
Quince Therapeutics to Participate in September 2026 Investor Conferences
September 3, 2026
Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
August 14, 2026
Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board
June 30, 2026